ArticlePhysiological reports2026
Targeted lipidomics between hPheo1 and SDHB KD cells reveal changes in bioactive lipids and PKC with polyamine pathway inhibition.
Article in Physiological reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pheochromocytoma and paraganglioma with a succinate dehydrogenase B subunit (SDHB) pathogenic variant are associated with a significant chance for metastasis. Polyamine pathway inhibitor N1,N11-diethylnorspermine (DENSPM) was previously shown to inhibit cell growth in progenitor cells derived from a human pheochromocytoma (hPheo1). Here, we hypothesized cell death associated with DENSPM treatment due to altered lipid metabolism affects protein kinase C (PKC). From targeted lipidomics analysis, baseline bioactive lipids that are distinct between the hPheo1 WT and SDHB KD cells are PE(P-18:1/16:0), PI(18:1/20:3), LPE(18:0), and LPE(22:4). With DENSPM treatment, the concentrations of multiple plasmanyl phosphatidylethanolamines (PE-O), sphingomyelins (SM), and hexosylceramides (HCER) increased, while the concentrations of several plasmenyl phosphatidylethanolamines (PE-P) were decreased in hPheo1 WT and SDHB KD cells. The differences in PE-Ps, PE-Os, and SMs after DENSPM treatment compared to the vehicle treatment were greater in the SDHB KD cells compared to the hPheo1 WT cells. Basal PKC alpha protein expression was increased in SDHB KD cells compared to hPheo1 WT cells. The protein expression of both PKC alpha and delta was significantly decreased with DENSPM treatment in both cell lines. DENSPM changed pro-caspase-3 and cleaved caspase-3. These data suggest ether phospholipids are biomarkers of DENSPM mediated cell apoptosis through a PKC dependent mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.